6533b831fe1ef96bd1298455

RESEARCH PRODUCT

Continuously manufactured magnetic polymersomes--a versatile tool (not only) for targeted cancer therapy.

Regina BleulMichael MaskosMichael MaskosGernot U. MartenRaphael ThiermannMichael J. HouseTimothy G. St. PierreUrs O. Häfeli

subject

BiodistributionRelaxometryMaterials scienceCell SurvivalMicromixerNanotechnologyAntineoplastic AgentsPoloxamerlaw.inventionPolyethylene GlycolsConfocal microscopylawCell Line TumorNeoplasmsmedicineHumansGeneral Materials SciencePrecision MedicineMagnetite NanoparticlesDrug CarriersCarbocyaninesPropylene GlycolsDrug deliveryPolymersomeMagnetic nanoparticlesBombesinCamptothecinCamptothecinmedicine.drug

description

Micromixer technology was used to prepare polymeric vesicles (Pluronic® L-121) dual loaded with the anti-cancer drug camptothecin and magnetic nanoparticles. Successful incorporation of the magnetic nanoparticles was confirmed by transmission electron microscopy. Dynamic light scattering measurements showed a relatively narrow size distribution of the hybrid polymersomes. Camptothecin polymersomes reduced the cell viability of prostate cancer cells (PC-3) measured after 72 h significantly, while drug-free polymersomes showed no cytotoxic effects. Covalent attachment of a cancer targeting peptide (bombesin) as well as a fluorescent label (Alexa Fluor® 647) to the hybrid polymersomes was performed and specific cell binding and internalization were shown by flow cytometry and confocal microscopy. Relaxometry measurements clearly demonstrated the capacity of magnetic polymersomes to generate significant T2-weighted MRI contrast and potentially allow for direct monitoring of the biodistribution of the polymersomes. Micromixer technology as an easy, fast and efficient way to manufacture hybrid polymersomes as theranostic drug delivery devices is a further step from basic research to personalized medicine.

10.1039/c3nr02190dhttps://pubmed.ncbi.nlm.nih.gov/23820598